PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12182627::ACT019135

C1

Evidence text

Paper-level observation

at the highest concentration (250 µg/mL), peptide C1 demonstrated ... 48.99% protection against ... HSV-2 in the CPE inhibition assay
textConfidence: high

Assay observation

Activity
Antiviral
Subtype
Anti-HSV
Measure
percent_inhibition
Comparator
=
Raw observation
48.99%
Normalized measurement
=48.99%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Vero
Assay method
Cytopathic effect (CPE) inhibition assay
Sequence
LQYPDDSDDE
Standardization
ready simple
Assay conditions
"250 µg/mL peptide, Vero cells infected with 10 TCID50 virus for 2 h, then peptide added. MTT readout after 5 days."

Source publication

Uncovering the Anti-Herpetic Activity of Anionic Peptides Derived From the Cytoplasmic Domain of Nectin-1.

Bioinformatics and Biology Insights · 2025

DOI 10.1177/11779322251344130 PMC12182627
Parent mention

Related peptide identities

PEPDIA-PLP-001878

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.